Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GGT1 | P19440 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8570761 | 0.80 | ALDH1A1 (0.48) | ALDH1A1CHRNB2CHRNB4CHRNA4HSD17B10 | |
| SCHEMBL8024200 | 0.80 | ALDH1A1 (0.36) | ALDH1A1GRM4CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL23771017 | 0.78 | ALDH1A1 (0.46) | ALDH1A1CHRNB2CHRNB4CHRNA4HSD17B10 | |
| SCHEMBL19634401 | 0.76 | ALDH1A1 (0.44) | ALDH1A1CHRNB2CHRNB4CHRNA4HSD17B10 | |
| SCHEMBL847978 | 0.75 | ALDH1A1 (0.37) | ALDH1A1GRM4CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL10046557 | 0.74 | ALDH1A1 (0.43) | ALDH1A1CHRNB2CHRNB4CHRNA4HSD17B10 | |
| SCHEMBL14205962 | 0.74 | ALDH1A1 (0.48) | ALDH1A1CHRNB2CHRNB4CHRNA4HSD17B10 | |
| SCHEMBL14675377 | 0.73 | ALDH1A1 (0.46) | ALDH1A1CHRNB2CHRNB4CHRNA4HSD17B10 | |
| SCHEMBL22842728 | 0.73 | ALDH1A1 (0.41) | ALDH1A1CHRNB2CHRNB4CHRNA4MEN1 | |
| SCHEMBL26417267 | 0.73 | ALDH1A1 (0.41) | ALDH1A1CHRNB2CHRNB4CHRNA4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130822-A1 | LOW TOXICITY NMP SUBSTITUTES AND USES THEREOF | ADVANCION CORPORATION | 2023-04-27 | — | — | US | disclosed |
| EP-4103550-A2 | LOW TOXICITY NMP SUBSTITUTES AND THEIR PREPARATION | ANGUS Chemical Company (US) | 2022-12-21 | — | — | EP | disclosed |
| CN-115335360-A | Low toxicity NMP substitutes and their preparation | 安格斯化学公司 | 2022-11-11 | — | — | CN | disclosed |
| WO-2021163348-A2 | LOW TOXICITY NMP SUBSTITUTES AND USES THEREOF | ANGUS CHEMICAL COMPANY (US) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130822-A1 | LOW TOXICITY NMP SUBSTITUTES AND USES THEREOF | NME4, NMBR, NMUR1 | ALDH1A1 1133/4885GRM4 2035/4885CHRNB2 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.